Previous 10 | Next 10 |
Gainers: EverQuote (NASDAQ: EVER ) +47% . NeoPhotonics Corporation (NYSE: NPTN ) +27% . Invacare Corporation (NYSE: IVC ) +23% . Adient plc (NYSE: ADNT ) +23% . Ducommun Incorporated (NYSE: DCO ) +22% . Insulet Corporation (NASDAQ: PODD ) +19% . Greenlight Capital Re (NASDAQ: G...
REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced it intends to offer and sell, subject to market and oth...
Gainers: Allakos (NASDAQ: ALLK ) +129% . MediWound (NASDAQ: MDWD ) +15% . Four Seasons Education (Cayman) (NYSE: FEDU ) +12% KemPharm (NASDAQ: KMPH ) +12% . Sandstorm Gold (NYSEMKT: SAND ) +11% . Endeavour Silver (NYSE: EXK ) +10% . MoneyGram International (NASDAQ: MGI )...
Allakos (NASDAQ: ALLK ) +97% on positive AK002 data and Q2 results . More news on: Allakos Inc., Riot Blockchain, Inc., Marathon Patent Group, Inc., Stocks on the move Read more ...
Thinly traded Allakos (NASDAQ: ALLK ) is up 77% premarket on increased volume following its announcement of positive data from a Phase 2 clinical trial, ENIGMA , evaluating lead candidate AK002 in patients with eosinophilic gastritis and/or eosinophilic gastroenteritis. More...
Allakos (NASDAQ: ALLK ): Q2 GAAP EPS of -$0.44 beats by $0.03 . More news on: Allakos Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the second quarter ended June...
Primary efficacy endpoint met with 95% reduction in gastrointestinal tissue eosinophils vs. 10% increase on placebo (p < 0.0001) Treatment response secondary endpoint met with 69% of AK002 treated patients meeting the response criteria vs. 5% on placebo (p = 0.0008) Total symptom...
Allakos (NASDAQ: ALLK ): Q1 GAAP EPS of -$0.47. More news on: Allakos Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
REDWOOD CITY, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the first quarter ended March 31, 2019. First Quarter 20...
News, Short Squeeze, Breakout and More Instantly...
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments – – Skin biopsies from subjects treated with AK006 show high receptor occupancy – – AK006 was well-tolerated with a favorable safety pro...
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chr...
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for...